Summary

Data from a randomized phase 3 trial indicate that vaginal brachytherapy (VBT) may be a better option than pelvic radiotherapy for treating high-intermediate risk (age>60 and stage 1C grade 1–2 or stage 1B grade 3; any age and stage 2A grade 1–2 or grade 3 with <50% invasion) endometrial cancers because of a lower rate of side effects, leading to enhanced quality of life. This article reports the results of the PORTEC-2 trial [NCT00376844].